Latest / Get Real with Jim Weiss / Frank Clyburn on Building Great Healthcare Companies

Transcript

Frank Clyburn on Building Great Healthcare Companies · Get Real with Jim Weiss

0:00
Speaker 1: Jim, I see you got your blazer on. Man.
0:02
Speaker 2: I do the Hollywood Reporter who I think we're going
0:04
Speaker 2: to do work with on some healthcare so much. You know,
0:08
Speaker 2: I've coined the phrase Hollywood and Healthcare that pertains to
0:12
Speaker 2: our Star Power group where we work with celebrities and
0:15
Speaker 2: influencers and that kind of work. Michael J. Fox and
0:18
Speaker 2: his wife Steph Curry, and Aisha Curry and John Mayer
0:22
Speaker 2: are all being honored today by the Hollywood Reporter for
0:25
Speaker 2: their social impact work. They invited me to come down,
0:29
Speaker 2: so I thought I'd engage with all those different folks
0:32
Speaker 2: who I think we may want to partner with down
0:34
Speaker 2: the road, get them on the podcast, that sort of thing.
0:37
Speaker 2: So it's awesome, similar to how we worked with Jim
0:41
Speaker 2: Kelly back in the day, you know, on Truda among others.
0:45
Speaker 2: Katie Curry, you know the deal absolutely. So look, I
0:48
Speaker 2: always like to start with an origin story number one.
0:51
Speaker 2: Thanks for joining the Real Chemistry Board. I'm very excited
0:54
Speaker 2: to be working with you after all the many years
0:58
Speaker 2: we've sort of run parallel live in this industry. But
1:01
Speaker 2: your dad was on the police force as a homicide
1:04
Speaker 2: detective in Philadelphia. I mean we're both Pennsylvania guys. That's cool.
1:08
Speaker 2: I was glad to know that. And I've got a
1:10
Speaker 2: lot of family there and one of the only actually
1:13
Speaker 2: black homicide detectives at the time, which I was a
1:17
Speaker 2: little surprised to hear. What did he bring home that
1:20
Speaker 2: shaped how you deal with the way the world works today?
1:24
Speaker 1: First, I'll start with Dad was kind of my hero, Jim.
1:27
Speaker 1: And if you think about it, he joined the military
1:30
Speaker 1: at a very early age. Even we looked and found
1:33
Speaker 1: some papers. I think he actually forged his age to
1:36
Speaker 1: be able to go to military very early because he
1:39
Speaker 1: had to help take care of the family. And he
1:42
Speaker 1: then progressed and came out of the military. He was
1:45
Speaker 1: in the police force and then ultimately became a homicide detective.
1:50
Speaker 1: Probably it was a couple things, Jim. One, it was
1:53
Speaker 1: clearly discipline, high expectations, kind of being the only one
1:59
Speaker 1: around the table and having to really show what he
2:02
Speaker 1: could do and prove empathy, big family guy, and then
2:06
Speaker 1: also probably got a little the competitive juices from Dad
2:10
Speaker 1: as well.
2:11
Speaker 2: Was he an athlete or and he's from born and
2:13
Speaker 2: raised Philadelphia?
2:14
Speaker 1: Also born and raised in Philadelphia. Yeah, Jim, he not
2:17
Speaker 1: really an athlete, but was very competitive person in wanting
2:23
Speaker 1: to really do and give his best, and in fact,
2:26
Speaker 1: he went on after the police force to build a
2:29
Speaker 1: couple of different businesses in Philadelphia. He was an entrepreneur
2:32
Speaker 1: as well.
2:33
Speaker 2: Oh wow, great, that's cool. Did you work in any
2:35
Speaker 2: of his businesses?
2:37
Speaker 1: I did, I did, Jim. He owned a restaurant bar
2:41
Speaker 1: and he may be familiar off a broad street in Philadelphia.
2:44
Speaker 1: Did that through kind of late actually, end of high
2:47
Speaker 1: school and in college during the summer.
2:49
Speaker 2: Awesome. So he was hyper focused on investing in an
2:54
Speaker 2: education for you kids, right, what do you think he
2:58
Speaker 2: was trying to give you that he didn't give himself.
3:01
Speaker 1: It was really clear from dad he was one, you know, Jim,
3:04
Speaker 1: and I've worked with a lot of smart people. My dad,
3:07
Speaker 1: I think was one of the brightest and smartest folks
3:09
Speaker 1: I ever knew, but didn't have the book smart Jim.
3:12
Speaker 1: He had to get out of high school, come out
3:14
Speaker 1: of high school early, and then go back for his ged.
3:18
Speaker 1: But he wanted the best education for both of myself.
3:22
Speaker 1: I have a twin sister.
3:23
Speaker 2: Okay, we didn't check that box. We both got twin sisters.
3:27
Speaker 1: Yeah, we do, we do. And he was really pushing us,
3:31
Speaker 1: and he really an early age. I guess I was
3:35
Speaker 1: one of those kids, Jim that was a little bit rambunctious,
3:39
Speaker 1: getting a lot of trouble, and in the third grade
3:42
Speaker 1: had me take the test for Pencharter and kind of
3:45
Speaker 1: Pinchart in the Philadelphia area one of the better private
3:49
Speaker 1: schools in Philadelphia. So I had a chance to go
3:52
Speaker 1: to Pencharter early on in third grade, and he pushed
3:55
Speaker 1: me to stay in Pincharter every year. I wanted to
3:58
Speaker 1: come out and go to the local schools because I
4:00
Speaker 1: had to commute to Pincharter from where we lived and
4:04
Speaker 1: go to local schools with my friends. But he pushed
4:06
Speaker 1: that and it was one of the best decisions. He
4:08
Speaker 1: was excited to see. I think both my sister and
4:12
Speaker 1: myself kind of do well in school, which then led
4:14
Speaker 1: me to go on to Franklin Marshall for undergrad Awesome.
4:18
Speaker 2: How did those school experiences shape you? Any big lessons there?
4:23
Speaker 1: I think a number of them, Jim. Probably the biggest
4:26
Speaker 1: one was the difference in socioeconomic status. Pincharter very competitive school, Jim,
4:32
Speaker 1: on the academic side, and it helped you to realize
4:36
Speaker 1: that you could compete and that you belonged and that
4:40
Speaker 1: you felt confident when you came out of a pin
4:43
Speaker 1: Charter and then ultimately when you came out of a
4:45
Speaker 1: Franklin Marshall. Yeah, it was just up at F and
4:47
Speaker 1: M recently, Jim earlier this year talking for a lot
4:50
Speaker 1: of students there do a lot of that. You know,
4:52
Speaker 1: it's a great institution.
4:54
Speaker 2: Yeah, tell me why what's the edge there that you
4:56
Speaker 2: found at Franklin Marshall.
4:58
Speaker 1: The well one F and M. Small schoo diplomats, you know,
5:01
Speaker 1: real small out in Leicester, PA. A lot of people
5:03
Speaker 1: don't even know about F and M.
5:05
Speaker 3: Jim, Well, we know Pennsylvanians now Pennsylvania as we know
5:09
Speaker 3: about it, if you know, you know, Yeah, very competitive
5:13
Speaker 3: academically and just really was an economic major, did a
5:18
Speaker 3: lot of work in the sciences as well, and I
5:21
Speaker 3: think it just really helped to shape kind of my
5:24
Speaker 3: view of some of the possibilities that we're out there.
5:27
Speaker 1: But I recommend it as a great undergrad school.
5:31
Speaker 2: So fast forward, what pulled you into healthcare? I always wonder.
5:35
Speaker 2: I'm on the board now of the Healthcare Women's Business
5:39
Speaker 2: Association Foundation Board, which is dedicated to bringing more and
5:46
Speaker 2: encouraging more kids to come into the healthcare field. What
5:51
Speaker 2: was it about healthcare that attracted you or did you
5:54
Speaker 2: just stumble into it like some of us.
5:56
Speaker 1: Did, that was more on the stumble side, Jim So,
5:59
Speaker 1: I stumbled in. Actually, it was a job fair down
6:02
Speaker 1: in Philadelphia. I was taking my buddy to go interview.
6:06
Speaker 1: He was looking to try to go out of school
6:09
Speaker 1: into Xerox, and I bumped into some folks from Marion Laboratories. Jim.
6:14
Speaker 1: I don't know if you remember maryon Labs inter city base,
6:18
Speaker 1: Ewing Kaufman, and bumped into some folks down there and
6:23
Speaker 1: they introduced me to Marion Labs at that time was
6:26
Speaker 1: a two hundred person company, really excited about what they
6:30
Speaker 1: were sharing, what they were doing, and that's how I
6:33
Speaker 1: entered into kind of the farm industry. First stroll pharmaceutical sales.
6:37
Speaker 1: Jym So. I started carrying to bag initially in my career.
6:40
Speaker 2: Boom, Well, yeah, and they always say you're supposed to
6:42
Speaker 2: do that. Was there a moment when you were carrying
6:45
Speaker 2: that bag that you knew this is the field for you?
6:49
Speaker 2: Or was there a point at any point that said
6:51
Speaker 2: I'm staying here, this is it, this is a great zone.
6:55
Speaker 1: I think it was when I'll never forget it, Jim.
6:58
Speaker 1: It was I was at a meeting with a couple
7:01
Speaker 1: of my key cardiology customers and when they really were
7:07
Speaker 1: sharing all of the scientific data what was happening in
7:10
Speaker 1: cardiovasca medicine, but the impact that one of the products
7:14
Speaker 1: I was representing and had on some of their patients.
7:18
Speaker 1: And I'll never forget that. Sitting in a hospital here
7:21
Speaker 1: in Central Jersey and I said, Wow, this is something
7:24
Speaker 1: that is going to be for me. And that was
7:26
Speaker 1: probably when the light went off connecting the impact of
7:31
Speaker 1: what the pharmaceutical industry does and the impact they had
7:34
Speaker 1: on patients and a bunch of cardiologists really discussing just
7:38
Speaker 1: the impact. And that was when I said, you know what,
7:42
Speaker 1: this is a great fit and kind of where I
7:43
Speaker 1: want to build my career.
7:45
Speaker 2: Awesome, Marion, was what you said. Two hundred people when
7:49
Speaker 2: you joined it, so really a relatives. What were you
7:52
Speaker 2: selling for them?
7:54
Speaker 1: So my first two products got Jim is you'll probably
7:58
Speaker 1: remember these Kartism TIRESM and Carafate to craw fit. Those
8:02
Speaker 1: were the two that was what was in the bag.
8:05
Speaker 1: And then it became some other products because Marian ended
8:08
Speaker 1: up becoming Mary and merle Dale and that was your
8:11
Speaker 1: Remember it was a lot of consolidation going on back then,
8:14
Speaker 1: and then it became then now all Is, and then
8:17
Speaker 1: it became Hirksman and Roussel, which became Adventist and then
8:20
Speaker 1: ultimately Santa Fia Ventis. But the first two products were
8:24
Speaker 1: Cardisan in carafe.
8:26
Speaker 2: Yeah, well, I came from the RPR side, so I know.
8:28
Speaker 1: Some remember, Yeah, I remember us talking about that.
8:31
Speaker 2: So I definitely remember. Again I said, we should have
8:34
Speaker 2: known each other long ago. But that's just the way
8:37
Speaker 2: the world works. Eventually. You do so across your time
8:40
Speaker 2: working in Farmer with merc now Revbad's and Cora Kolera,
8:45
Speaker 2: among others, you've repeated that your focus is on the patient,
8:50
Speaker 2: which we hear a lot. How can you spot when
8:52
Speaker 2: a company is patient first and what happens when that's
8:57
Speaker 2: not the case. Have you had to get them right now?
9:02
Speaker 1: I think Jim I always say, and I've been very
9:04
Speaker 1: blessed him to work with some great companies and I
9:07
Speaker 1: really probably the one that I reflect back on now,
9:11
Speaker 1: which is more recent, is Merk And if you recall
9:15
Speaker 1: or you probably aware is you can tell both from
9:20
Speaker 1: the vision the mission, and I'll give you some examples, Jim,
9:23
Speaker 1: but probably the quote that George Murk had was probably
9:26
Speaker 1: the most impactful one for me, where he said, we
9:30
Speaker 1: try to remember the medicines for the patients and never
9:33
Speaker 1: forget that medicine is for the people and not for profit.
9:37
Speaker 1: And a lot of people have slogans, but George went
9:40
Speaker 1: on to say, if we remember that, the profits have
9:43
Speaker 1: never failed to appear. And I always thought about that,
9:49
Speaker 1: and I said, if we do what is right around
9:51
Speaker 1: the patient and having impact, then you're going to see
9:56
Speaker 1: and drive all of the financial metrics that you need
9:58
Speaker 1: to drive to have a sustain a able successful company.
10:02
Speaker 1: And as I had a chance, and you see that
10:04
Speaker 1: with Revolution Medicine and the work I'm doing with that team.
10:09
Speaker 1: You see it with Kayleira, with Zincora. Is you know,
10:12
Speaker 1: you can really spot a gem through the leadership and
10:16
Speaker 1: through you know, the senior leadership the team. You can
10:20
Speaker 1: spot it through culture. I always say culture is a
10:23
Speaker 1: lot of times what people do when nobody's watching gim
10:26
Speaker 1: and you can really feel and see the passion of
10:29
Speaker 1: people when you're walking around and engaging with them and
10:33
Speaker 1: what they're focused on So those are some of the
10:35
Speaker 1: things that you're able to see and look for, and
10:37
Speaker 1: when you don't see that, I think you have to
10:40
Speaker 1: constantly bring that to the forefront as a board member
10:44
Speaker 1: or as an advisor to help make sure the leadership
10:46
Speaker 1: team is really focused on those things, the values and
10:49
Speaker 1: the culture for the company.
10:50
Speaker 2: Well, it's just interesting we came up in the industry.
10:53
Speaker 2: You know, there wasn't direct consumer advertising. There weren't a
10:57
Speaker 2: lot of the things that we employ today. But also
11:02
Speaker 2: the impression of the industry I feel like was more heroic,
11:06
Speaker 2: I guess is the only other idea I can think of,
11:09
Speaker 2: and more more positive. What do you think changed and
11:13
Speaker 2: then put us in a position of cocktail parties to explain,
11:16
Speaker 2: you know, sort of what we do is good and
11:20
Speaker 2: not bad.
11:22
Speaker 1: Yeah, and that's been a tough one, Jim, you mentioned it.
11:25
Speaker 1: I think one there were probably some bad actors as
11:29
Speaker 1: I think back on the pricing aspect of what we've
11:32
Speaker 1: done in the industry, Jim, So we know who some
11:35
Speaker 1: of those folks are too. I do think that we're
11:39
Speaker 1: a unique industry and pharma where there's you know, intermediate
11:44
Speaker 1: areas and you don't have as direct a relationship with
11:48
Speaker 1: the end customer that's changing significantly. We'll talk a little
11:51
Speaker 1: bit more about that, which I think is a positive
11:53
Speaker 1: you can help the industry. I would say those are
11:55
Speaker 1: probably the couple things. And then if you look at
12:00
Speaker 1: at just patients and some of them realistically have challenges
12:05
Speaker 1: out of pocket costs Jim copays, some of those things
12:10
Speaker 1: really impact the ability and affordability for some patients that
12:14
Speaker 1: the industry obviously is trying to address the probably good
12:16
Speaker 1: needs to do. Some continue to work in those areas.
12:19
Speaker 2: You helped turn Cutrude into one of the most important
12:22
Speaker 2: cancer medicines in history. I was lucky enough to work
12:26
Speaker 2: in the early days of her step then and of
12:28
Speaker 2: asking some of those that have done incredible things for
12:32
Speaker 2: patients in the in the field, when did you realize
12:37
Speaker 2: it was something that could change care.
12:39
Speaker 1: I think there were a couple of oh my gosh moments,
12:42
Speaker 1: Jim and I was very fortunate to work with a
12:45
Speaker 1: great team at merk on Contruda and just the entire
12:49
Speaker 1: clinical R and D team, commercial team. The Aha moments,
12:54
Speaker 1: Jim was one when we saw our melanoma data and
12:58
Speaker 1: we were seeing the door ability of the responses and
13:01
Speaker 1: that was early on. That was our first indication was
13:04
Speaker 1: kind of in melanoma and you could see the patient impact.
13:09
Speaker 1: The other AHA moment was probably when we were able
13:12
Speaker 1: to present the ASCO data for I remember this keynote
13:15
Speaker 1: twenty four. It was lung data. It was the first
13:18
Speaker 1: line lung cancer data where we showed a significant effect
13:23
Speaker 1: size and benefit for lung cancer patients. And then it
13:25
Speaker 1: was like, oh my gosh, I had worked in lung
13:30
Speaker 1: and in oncology at Santa Fe for docal taxil taxi
13:33
Speaker 1: tier and that was the comparative, so that was kind
13:35
Speaker 1: of the standard. Okay, when you saw Contru's impact worked
13:38
Speaker 1: on that too, kind of said, oh my goodness, an
13:41
Speaker 1: impact is huge. And then probably the third was when
13:45
Speaker 1: we realized we had something foundational. We did a basket
13:48
Speaker 1: study across multiple different cancer types and we were seeing
13:53
Speaker 1: response rates across So I think those were kind of
13:56
Speaker 1: the AHA moments which allowed us to really then to
13:59
Speaker 1: build out the product in the franchise and we thought
14:02
Speaker 1: that this could truly be a pipeline in a product.
14:04
Speaker 2: Can you remember any individual patients or stories. We can
14:09
Speaker 2: talk about the big curves, but to a patient who's
14:13
Speaker 2: going through this and a family. It only counts for them, so.
14:17
Speaker 1: I'll never forget Jim. There were two letters that I received,
14:24
Speaker 1: and that's to me, to your point, Jim, the most
14:26
Speaker 1: impact when we were working on contruda. One was a
14:28
Speaker 1: lung cancer patient and it was and it's like I
14:33
Speaker 1: read it yesterday, Jim. He was late stage stage three
14:37
Speaker 1: to four lung cancer and those of us who work
14:41
Speaker 1: in long no, when you get that type of diagnosis,
14:44
Speaker 1: it's usually not good. And he wrote a letter a
14:49
Speaker 1: year after he had been on Contruda. He didn't think
14:52
Speaker 1: he was going to make it a year, and he
14:54
Speaker 1: actually had a chance to see his daughter get married,
15:00
Speaker 1: and then ultimately he wrote a follow up and had
15:04
Speaker 1: a chance to actually see his first granddaughter. Yeah, so
15:08
Speaker 1: that's one. And then there was another was a female
15:13
Speaker 1: lady who had triple negative breast cancer, which is a
15:15
Speaker 1: really challenging diagnosis as well TNBC that had just a
15:21
Speaker 1: remarkable response and also wrote a letter in about just
15:26
Speaker 1: how it's changed our quality of life and gave her hope.
15:29
Speaker 1: So those to me, Jem, it's those two examples. There
15:33
Speaker 1: were a lot of things that you kind of remember
15:36
Speaker 1: back to those days, but those two kind of really
15:38
Speaker 1: stick out that these are patients and people that were
15:41
Speaker 1: not expecting to maybe have the ability to be a
15:44
Speaker 1: part of, you know, their son or daughter's life, and
15:47
Speaker 1: seeing those type of events, that's when you know that
15:50
Speaker 1: you're really having an impact. And that's what honestly, that's
15:53
Speaker 1: what drives me to this day, Jim. That's what kind
15:55
Speaker 1: of gets you up and gets you started.
15:57
Speaker 2: That's why we do it right and on our twenty
15:59
Speaker 2: fifth year, we're out talking about that when it only
16:02
Speaker 2: gets more impactful as we expand our global footprint and reach,
16:07
Speaker 2: and the fact that these medicines affect people all over
16:11
Speaker 2: the world, in the smallest towns and the biggest cities,
16:14
Speaker 2: in the most remote places. It's pretty remarkable how many
16:17
Speaker 2: of those stories are there.
16:18
Speaker 1: There's so many, there's a lot of them.
16:21
Speaker 2: Jim. Yeah, So when you're sitting in these board meetings,
16:24
Speaker 2: do talk of the breakthrough science overshadow the focus on
16:30
Speaker 2: getting it too patients. And that's why you're sitting there
16:32
Speaker 2: right because they usually put someone like you on the board,
16:35
Speaker 2: particularly in the early stages, to kind of think with
16:38
Speaker 2: the end in mind, keep everybody honest that, look, we're
16:41
Speaker 2: going to get this drug out there. It's not just
16:44
Speaker 2: the data and the science which you have to have
16:47
Speaker 2: to get approval and prove your point in your opinion,
16:50
Speaker 2: what's moving faster innovation? Where are we on affordability, accessibility,
16:57
Speaker 2: all those elements both.
16:59
Speaker 1: Are I would say it's a probably key on the
17:01
Speaker 1: board agenda this gym both topics, right, So I think
17:05
Speaker 1: innovation is probably moving a little bit Fastim, because you're
17:08
Speaker 1: saying just I mean unbelievable innovation that's coming out of
17:14
Speaker 1: labs right now. Obviously we could talk at nauseum about
17:17
Speaker 1: what we believe in selling gene therapy. You're saying, anybody
17:20
Speaker 1: drugchondric gets a lot of innovation coming out. So there's
17:23
Speaker 1: a lot of speed and focus there. The access piece, Jim,
17:28
Speaker 1: where I really try to you always want to start
17:31
Speaker 1: with everything that you're working on from an innovation perspective
17:34
Speaker 1: to your point, and this is where we'll get into
17:36
Speaker 1: real CAM has to translate into being able to have
17:41
Speaker 1: a patient benefit or impact, which starts then, obviously with
17:46
Speaker 1: accessibility and making sure patients can get the medications they
17:49
Speaker 1: can afford them. So we spent a lot of time
17:51
Speaker 1: on both gym. I think innovation's moving very rapid. But
17:57
Speaker 1: I do also think as you're seeing now companies and
18:00
Speaker 1: working more directly with patients for self pay programs and
18:05
Speaker 1: those kinds of things, there's a lot of innovation taking
18:07
Speaker 1: place in the access front as well. But if you
18:09
Speaker 1: ask me, innovations a little bit faster than what the
18:12
Speaker 1: work on the access.
18:13
Speaker 2: We are making progress in both.
18:15
Speaker 1: We're making progress, is what I would say. In both, Jim, and.
18:18
Speaker 2: You help do that. People talk about the drug price tag,
18:21
Speaker 2: not the billions spent on the pipelines that fail before
18:25
Speaker 2: one drug makes it to market. How can we fix
18:28
Speaker 2: the misconception about the pharmaceutical model, because that's the thing
18:33
Speaker 2: we do here at These things cost too much when
18:35
Speaker 2: you think about the stories, it's hard to believe that.
18:38
Speaker 1: But okay, yeah, no, Jim, it's real though, and I
18:41
Speaker 1: think it's something the industry has been grappling with. Honestly,
18:44
Speaker 1: in my previous roles, that's the challenge, right, So it's
18:47
Speaker 1: continuing education. I do think, Jim, what you're seeing though,
18:51
Speaker 1: is now and it's happening really in the obesity space
18:55
Speaker 1: very quickly, where companies have now actually gone going to
19:00
Speaker 1: a lot of their oral medications that are getting approved
19:04
Speaker 1: or self paid JAM, so they're having direct relationships with
19:08
Speaker 1: the patient. And it's very interesting to see that patients
19:13
Speaker 1: are spending out of pocket for that innovation. And I've
19:16
Speaker 1: spoken to a number of patients that are taking these
19:20
Speaker 1: products and they're seeing the benefit JAM, so they're connecting
19:24
Speaker 1: the actual benefit to what they're paying out of pocket.
19:28
Speaker 1: And I think those are some things that are starting
19:31
Speaker 1: to hopefully change the narrative of what the industry is doing,
19:35
Speaker 1: all of the research and development dollars that go into
19:40
Speaker 1: bring something to market. I think if you could connect
19:44
Speaker 1: greater with that patient, I do think that's how you
19:46
Speaker 1: start to help just change some of the narrative that
19:49
Speaker 1: people can start to realize that what is being done
19:52
Speaker 1: is really having a huge impact on my lifestyle, health outcomes,
19:56
Speaker 1: in the quality of life.
19:57
Speaker 2: So do you think there's a path to making everything
19:59
Speaker 2: more affordable? I ask about AI all the time. Cannot
20:03
Speaker 2: speed the time to market. The longer we can be
20:06
Speaker 2: on the market, probably arguably you can charge less so
20:10
Speaker 2: you have more time to make up the investment costs.
20:13
Speaker 2: Is that something we can expect going forward from AI?
20:17
Speaker 1: I think so, Jim. I think there's a lot of
20:19
Speaker 1: encouraging signals still work to be done. I look at
20:21
Speaker 1: it across the entire value chain for the companies you
20:25
Speaker 1: start in discovery, GEM and target identification, all the way
20:29
Speaker 1: early on to roof of concept, translational medicine, getting the product.
20:34
Speaker 1: You think about your clinical trial footprint. AI can help there.
20:37
Speaker 1: It can help across so many different aspects of the model.
20:42
Speaker 1: And then once you through development, think about your supply
20:45
Speaker 1: chain and manufacturing GEM and everything that you can do
20:48
Speaker 1: from a working capital perspective, and how AI can help there.
20:52
Speaker 1: And then we'll talk a little bit more about just
20:54
Speaker 1: the commercialization of these products and better messaging, better targeting
20:59
Speaker 1: can all so be very impactful on helping to be
21:03
Speaker 1: more effective and efficient. So all of those things across
21:06
Speaker 1: the entire value chain I think can help us do
21:09
Speaker 1: a better job of once getting the right medications to
21:13
Speaker 1: the right patients.
21:14
Speaker 2: So at real chemistry, we're working at the intersection of
21:17
Speaker 2: healthcare communications, even AI. What attracted you to help us?
21:23
Speaker 2: Why did you come here? What was interesting about working?
21:27
Speaker 2: I mean, obviously you've been a marketer or your whole career,
21:29
Speaker 2: So is that one of the things that made this
21:32
Speaker 2: interesting versus a typical R and D company that would
21:36
Speaker 2: eventually commercialize a drug, we help them commercialize. So it's
21:39
Speaker 2: a little different.
21:41
Speaker 1: Yeah. So if you think about where we started, Jim,
21:44
Speaker 1: and what was attractive for me with real Cam was
21:48
Speaker 1: obviously I knew about real Chemistry from our communications team
21:53
Speaker 1: and the teams that I were at marking the work,
21:55
Speaker 1: the phenomenal work that was done on Contruder, so we
21:57
Speaker 1: talked about contruders. So I knew about real Chemistry as
22:02
Speaker 1: an industry leader and all of the capabilities that was bringing.
22:06
Speaker 1: But it was also a chance, I think Jim to
22:08
Speaker 1: have an impact on how we transform and really help
22:14
Speaker 1: the commercialization of all of the innovation that's coming out
22:17
Speaker 1: of these companies. I mean, if I think about what
22:20
Speaker 1: we're doing in medical communications, Jim, I think about just
22:25
Speaker 1: the work that the team is doing in all of
22:28
Speaker 1: its integrated communications and activations and the analytical work that
22:34
Speaker 1: supports real Kim. I just was really excited when I
22:38
Speaker 1: had a chance to take a look and said, this
22:40
Speaker 1: is a company that can have a huge impact on
22:44
Speaker 1: how products are commercialized. And obviously, being the former head
22:49
Speaker 1: of a commercial for a pretty large company, I could
22:53
Speaker 1: see what capabilities and what Real chem is today and
22:56
Speaker 1: then think about where we have the opportunity, and we
23:00
Speaker 1: just announced and are an acquisition out in Asia Pacific
23:04
Speaker 1: region and all the things that we can bring even
23:06
Speaker 1: globally for Real cam. That was all exciting, so all
23:09
Speaker 1: those things and me want to be a part of a
23:12
Speaker 1: team to help out to drive that.
23:14
Speaker 2: Yeah, I mean, I think you're going to help us.
23:15
Speaker 2: We worked in parallel. We got a different name back
23:18
Speaker 2: from the day when we worked on Key Trudea. But
23:21
Speaker 2: maybe hard to track and follow that. But Real Chemistry
23:24
Speaker 2: is going to benefit from your knowledge and reach and
23:28
Speaker 2: influence in the industry. I'm really, as I said, excited
23:32
Speaker 2: to get out there and tell everybody how we can
23:35
Speaker 2: help them and what we can do. There's still so
23:37
Speaker 2: much more upside there. But before we get to the
23:40
Speaker 2: fun questions, I always ask, Now, you're on the board
23:43
Speaker 2: of this obesity Company's one of my favorite topics is obesity.
23:47
Speaker 2: These drugs are not just targeting obesity, they're changing lives
23:51
Speaker 2: really from a physical and mental health standpoint. I would
23:55
Speaker 2: argue more than AI, these golp ones and this whole field,
24:00
Speaker 2: we'll revolutionize humankind. What's it like sitting on that board
24:04
Speaker 2: and what are you excited about in terms of what's
24:07
Speaker 2: next for this category.
24:09
Speaker 1: I'm really excited and we're working on kind of next
24:12
Speaker 1: gen of ration Obcity products. We think we've got an
24:15
Speaker 1: opportunity to have the potential of category leading weight loss
24:19
Speaker 1: and it's still unmet need Jim, in the space, and
24:23
Speaker 1: also really good tolerability because that's also really important for
24:27
Speaker 1: these products and for BMI of thirty five plus high BMI,
24:31
Speaker 1: we still think there's unmet need and opportunity and that's
24:34
Speaker 1: what Calera Kyleiras focused and as you mentioned, it's great
24:38
Speaker 1: to see some of the other benefits everyone. When I
24:41
Speaker 1: started and was discussed about OBEs, people thought it was
24:46
Speaker 1: more kind of lifestyle Jim, and it wasn't really an
24:50
Speaker 1: important innovation.
24:51
Speaker 2: And I think more that it wasn't really a disease.
24:53
Speaker 1: He wasn't really a disease, and people were like, it's
24:57
Speaker 1: not really a disease, and if you focus on the
24:59
Speaker 1: diet and exerc that was more of a lifestyle kind
25:02
Speaker 1: of view of it. And I think that has changed
25:04
Speaker 1: significantly because as you mentioned, Jim, you're just seeing the
25:07
Speaker 1: benefit across just so many different aspects of cardiovascor health
25:13
Speaker 1: and the positive outcomes, and I see it in patience
25:18
Speaker 1: every day, just the lifestyle change that they're having and
25:20
Speaker 1: the impact. So that's what we're really excited about why
25:23
Speaker 1: I wanted to work with the team at Kaileira.
25:26
Speaker 2: You start to lose weight, you're able to get out,
25:29
Speaker 2: you're able to move around EASi or it kind of
25:32
Speaker 2: creates a cascade of healthier behavior almost incidentally, it's not
25:37
Speaker 2: even something you're even thinking about. And of course you
25:40
Speaker 2: got to keep your muscle tone and all the rest.
25:43
Speaker 1: Yeah, I'm really excited about just the possibilities and the
25:46
Speaker 1: opportunity Jim. And as you mentioned, which has been kind
25:49
Speaker 1: of a part of where I wanted to spend time,
25:53
Speaker 1: is just having an impact on healthcare. And this is
25:56
Speaker 1: the beauty of having a chance to work with the
25:59
Speaker 1: companies I work with now across just the entire healthcare
26:03
Speaker 1: ecosystem and spectrum with the goal of helping patients and
26:08
Speaker 1: helping people to just have a greater life and lifestyle
26:11
Speaker 1: and impact.
26:12
Speaker 2: What are you in particular getting real about right now
26:15
Speaker 2: beyond that, Well, the.
26:17
Speaker 1: Big thing now, Jim, I'm getting real about is spending time,
26:22
Speaker 1: which you know, I have a son now, Jim, that
26:24
Speaker 1: just came out of Stern and he's up at new
26:27
Speaker 1: Balance and he's doing just tremendous work. But it's you know,
26:31
Speaker 1: you go through these career journeys in life and you
26:34
Speaker 1: look up and you're like, wow, You've got crown kids.
26:37
Speaker 1: So I'm getting real about trying to spend time family
26:42
Speaker 1: friends and also wanting to spend a lot of time
26:45
Speaker 1: on mentoring and just helping, helping the next generation. So
26:48
Speaker 1: I'm doing that.
26:49
Speaker 2: So you're not going to become a Celtic fan now, probably.
26:52
Speaker 1: Not, And now more than ever that the Jalen Brown
26:57
Speaker 1: is moving to Philadelphia. So I always been a big
27:01
Speaker 1: Sixer fan, and we're really excited. I was waiting for
27:03
Speaker 1: you to bring it up. We're really excited in Philadelphia
27:07
Speaker 1: right now.
27:08
Speaker 2: We'll make sure we hang out with Jellen here and there.
27:11
Speaker 2: But as you know, I'm a die hard Warrior fan.
27:13
Speaker 2: But the Sixers do hold a special place in my heart,
27:17
Speaker 2: as do the next So there's a lot of great
27:18
Speaker 2: East Coast teams, believe it or not. So listen, if
27:22
Speaker 2: there was an album that's the soundtrack of your life,
27:25
Speaker 2: what would that be.
27:26
Speaker 1: It's a simple one. Jim, it's an Earth winning fire
27:29
Speaker 1: my friend.
27:30
Speaker 2: Oh wow, I don't think we've heard that one.
27:32
Speaker 1: E WF. That's the way of the world, big Earth
27:36
Speaker 1: winning firefan you signing, you'd be like dad, you know
27:39
Speaker 1: that's kind of old school. You know what about this
27:41
Speaker 1: and jay Z and that one in that But it's
27:44
Speaker 1: e WF.
27:44
Speaker 2: So you're one of the people when they place September,
27:47
Speaker 2: you get up.
27:48
Speaker 1: And start You got it? I love it. Well, I
27:50
Speaker 1: still go see them.
27:51
Speaker 2: No, I know they're still going.
27:53
Speaker 1: They're still going. Jim was a documentary by the way,
27:55
Speaker 1: it was just out. I think Michelle and Barack Obama
27:59
Speaker 1: just so. I think they were producing a documentary on
28:01
Speaker 1: the EWF. It was great. But yeah, they're still going.
28:05
Speaker 2: Awesome. Love it. And what's your favorite vacation?
28:08
Speaker 1: Oh? Favorite vacation Turks and Caicos.
28:11
Speaker 2: Okay, there's a definite run up of that one. Everybody
28:15
Speaker 2: loves that.
28:16
Speaker 1: Everybody's loving Turks. We went years ago. I a good
28:20
Speaker 1: friend of mine as a place down here Jim and
28:22
Speaker 1: was telling me about Turks and it was before it
28:24
Speaker 1: became as popular, but it's been one of our favorite
28:27
Speaker 1: vacation places. My wife had a milestone birthday there where
28:32
Speaker 1: the whole family came and it was just tremendous time.
28:35
Speaker 1: So that's kind of our as my wife says, our
28:38
Speaker 1: happy her happy place. So we love it. Yeah, love Turks.
28:41
Speaker 2: I was wondering, you know, a lot of people ask
28:43
Speaker 2: beach or mountain or country or city or whatever, but
28:47
Speaker 2: sounds like you got the answer, and I know a
28:49
Speaker 2: lot of people love that place. So Frank, thanks for
28:52
Speaker 2: taking a few minutes. We're thrilled to have you on
28:54
Speaker 2: the board. We're excited to work with you. All of
28:57
Speaker 2: our clients say hello, particular Courtney Ronaldo, but there's a
29:01
Speaker 2: bunch of others that we work with who love, admire
29:05
Speaker 2: and respect you. So excited to make impact together. Thanks
29:09
Speaker 2: for being here.
29:10
Speaker 1: Thank you, Jim, appreciate it and really excited about the
29:13
Speaker 1: future and working with you and the team as we move.
29:15
Speaker 1: Thanks forward. Jim.
29:17
Speaker 2: Hey everyone, thanks for watching. I really appreciate that you
29:20
Speaker 2: take the time to listen to this and tune in,
29:24
Speaker 2: so please subscribe, follow We've got a lot of amazing guests.
29:28
Speaker 2: You're gonna learn a lot and you're gonna feel a
29:30
Speaker 2: lot better because you did it.